Progyny Inc logo

Progyny Inc(PGNY)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
5-STAR RATING
STRONG BUY
BUY for 18 days
PROFIT SINCE LAST BUY
+27.22% ▲
LAST CLOSE
$36.18
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for PGNY

11/13/2026: PGNY (5-star) is a STRONG-BUY. BUY for 18 days. Simulated Profits (27.22%). Updated daily EoD!

Progyny Inc is a specialized benefits management company focused on providing fertility and family-building support to large employer clients. Its primary strength lies in its high-touch service model and data-driven network of fertility specialists, which help improve clinical outcomes and manage costs for self-insured companies. The investment story centers on the continued expansion of corporate fertility benefits as a standard offering, providing a significant runway for growth. Key risks include heavy client concentration, potential competition from large health insurers, and economic sensitivity affecting corporate budgets. The stock may best suit growth-oriented investors, while those monitoring the company should track client retention rates and expansion into new employer segments.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitProgyny operates in a high-growth sector with significant penetration potential in the large-employer market.
Momentum investorMixed fitPerformance is highly sensitive to earnings surprises and growth outlooks, requiring a positive momentum signal.
Value investorWeak fitThe company often trades at premium valuations typical of high-growth healthcare services, limiting value-based entry points.
Dividend investorWeak fitProgyny does not pay a dividend, prioritizing capital allocation for market share growth.
Low-risk investorWeak fitThe stock exhibits significant price volatility related to market sentiment toward growth-oriented healthcare stocks.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighGrowth-stage companies in the healthcare sector often experience significant price swings based on quarterly results.
Valuation riskMedium / highThe stock can be highly sensitive to changes in growth expectations relative to its current price multiples.
Competition risk (Digital health platforms)Medium / highIncreased competition from well-capitalized insurance carriers could pressure margins and market share.
Business qualityMediumWhile the service model is highly regarded, the company relies heavily on a limited number of enterprise contracts.
Dividend incomeLow / noneInvestors seeking income will not find a dividend-paying investment here.
Execution riskMediumThe ability to successfully scale operations while maintaining service quality for a growing client base is paramount.

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 2.66B USD
Price to earnings Ratio 33.5
1Y Target Price 37.25
Price to earnings Ratio 33.5
1Y Target Price 37.25
Volume (30-day avg) 1.1M shares
Beta 0.95
52 Weeks Range 16.10 - 37.16
Updated Date 11/14/2026
52 Weeks Range 16.10 - 37.16
Updated Date 11/14/2026
Dividends yield (FY) -
Basic EPS (TTM) 1.08

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Healthcare Plans

BUY participation
60.0%
Active BUY / eligible
3 / 5
30-Day BUY Count Change
+1

Eligible universe: 5 stocks.

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit 93.16%
Avg. Invested days 44
Today’s Advisory Strong Buy
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 4.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
PGNY receives a 4-star rating, supported by solid company fundamentals, and solid analyst coverage. The rating is constrained by limited analyst upside.

Company Fundamentals

★★★★★
PGNY has solid overall fundamentals (4 stars), with moderate financial health, moderate growth momentum, and solid ownership. In FY2025 versus FY2024, moderate earnings growth (+7.7%) and solid cash generation (FCF margin 14.9%) are partially offset by soft profitability (net margin 4.5%), modest insider ownership of 2.01%.

Financial Health Rating

★★★★★
PGNY's financial health is supported by solid liquidity, including working-capital and asset support (WC/assets 47.1%). Profitability is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is PGNY's strongest growth driver at +10.4% FY2025 versus FY2024 (solid, 4 stars). Revenue growth (+10.4%, solid) and earnings growth (+7.7%, moderate) are also constructive, though not equally high across every growth measure.

Ownership

★★★★★
Institutional ownership is 113.9% and approximately 91.1% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 2.01% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

BlackRock Inc 15.75%
FMR Inc 9.51%
Vanguard Portfolio Management, LLC 6.82%
Vanguard Capital Management, LLC 4.36%
State Street Corp 4.10%

Unit Economics (Per $1K Revenue)

★★★★★
PGNY generates approximately $236 of gross profit, $66 of operating income, and $149 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Soft margins and solid cash conversion support a 3-star rating, while capital efficiency is moderate.

Economic Dimensions

★★★★★
Effective Tax Rate: 38.68%

Quantitative Style Profile

★★★★★
PGNY has a high-quality, liquid profile. Valuation that is moderately attractive rather than deeply discounted is the primary drawback.

Style Classification

Quality Focused

Quality TiltSmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Fertility Benefits ManagementRevenue generated from management fees and utilization-based service fees from employer clients.This is the primary revenue stream, scaling as the company wins more employer contracts.
Pharmacy BenefitsRevenue from the administration and provision of fertility-related prescription medications.This segment provides an integrated, high-margin revenue stream that compliments the core services.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date 2026-11-04
When After Market
Estimate 0.27
Actual 0.31

Profitability

Profit Margin 6.8%
Operating Margin (TTM) 9.97%

Management Effectiveness

Return on Assets (TTM) 11.34%
Return on Equity (TTM) 18.69%

Valuation

Trailing PE 33.5
Forward PE 15.38
Enterprise Value 2.52B
Price to Sales(TTM) 1.99
Enterprise Value 2.52B
Price to Sales(TTM) 1.99
Enterprise Value to Revenue 1.88
Enterprise Value to EBITDA 19.04
Shares Outstanding 73.65M
Shares Floating 67.12M
Shares Outstanding 73.65M
Shares Floating 67.12M
Percent Insiders 2.01
Percent Institutions 113.9

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.